Table of Contents Author Guidelines Submit a Manuscript
Clinical and Developmental Immunology
Volume 2011 (2011), Article ID 316314, 6 pages
http://dx.doi.org/10.1155/2011/316314
Research Article

Expansion of CD16-Negative Natural Killer Cells in the Peripheral Blood of Patients with Metastatic Melanoma

1Division of Hematology, Department of Medicine, Mayo Clinic Graduate School of Medicine, 200 First Street SW, Rochester, MN 55905, USA
2Department of Oncology, Mayo Clinic Graduate School of Medicine, 200 First Street SW, Rochester, MN 55905, USA
3Department of Obstetrics and Gynecology, Mayo Clinic Graduate School of Medicine, 200 First Street SW, Rochester, MN 55905, USA
4Department of Immunology, Mayo Clinic Graduate School of Medicine, 200 First Street SW, Rochester, MN 55905, USA

Received 14 October 2010; Revised 17 December 2010; Accepted 17 January 2011

Academic Editor: Ronald Herberman

Copyright © 2011 Shernan G. Holtan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. I. Waldhauer and A. Steinle, “NK cells and cancer immunosurveillance,” Oncogene, vol. 27, no. 45, pp. 5932–5943, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. P. Hersey, A. Edwards, M. Honeyman, and W. H. McCarthy, “Low natural killer cell activity in familial melanoma patients and their relatives,” British Journal of Cancer, vol. 40, no. 1, pp. 113–122, 1979. View at Google Scholar · View at Scopus
  3. V. Jović, G. Konjević, S. Radulović, S. Jelić, and I. Spuzić, “Impaired perforin-dependent NK cell cytotoxicity and proliferative activity of peripheral blood T cells is associated with metastatic melanoma,” Tumori, vol. 87, no. 5, pp. 324–329, 2001. View at Google Scholar · View at Scopus
  4. C. Romagnani, K. Juelke, M. Falco et al., “CD56CD16 killer Ig-like receptor NK cells display longer telomeres and acquire features of CD56 NK cells upon activation,” Journal of Immunology, vol. 178, no. 8, pp. 4947–4955, 2007. View at Google Scholar · View at Scopus
  5. D. Rukavina, E. R. Podack, G. Rubesa, S. Suzana-Pandelo, and L. Randic, “Down-regulated expression of perforin-positive/CD16 cells in the peripheral blood lymphocytes in the first trimester of pregnancy and up-regulation at the end of pregnancy,” American Journal of Reproductive Immunology, vol. 38, no. 3, pp. 189–196, 1997. View at Google Scholar · View at Scopus
  6. A. Moffett-King, “Natural killer cells and pregnancy,” Nature Reviews Immunology, vol. 2, no. 9, pp. 656–663, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. L. A. Koopman, H. D. Kopcow, B. Rybalov et al., “Human decidual natural killer cells are a unique NK cell subset with immunomodulatory potential,” Journal of Experimental Medicine, vol. 198, no. 8, pp. 1201–1212, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. D. B. Keskin, D. S. J. Allan, B. Rybalov et al., “TGFβ promotes conversion of CD16 peripheral blood NK cells into CD16 NK cells with similarities to decidual NK cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 9, pp. 3378–3383, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. L. Yang, Y. Pang, and H. L. Moses, “TGF-β and immune cells: an important regulatory axis in the tumor microenvironment and progression,” Trends in Immunology, vol. 31, no. 6, pp. 220–227, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. W. J. Chng, G. B. Tan, and P. Kuperan, “Establishment of adult peripheral blood lymphocyte subset reference range for an asian population by single-platform flow cytometry: influence of age, sex, and race and comparison with other published studies,” Clinical and Diagnostic Laboratory Immunology, vol. 11, no. 1, pp. 168–173, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. M. C. Lygnos, K. I. Pappa, H. A. Papadaki et al., “Changes in maternal plasma levels of VEGF, bFGF,TGF-β, ET-1 and sKL during uncomplicated pregnancy, hypertensive pregnancy and gestational diabetes,” In Vivo, vol. 20, no. 1, pp. 157–163, 2006. View at Google Scholar · View at Scopus
  12. K. Krasagakis, D. Thölke, B. Farthmann, J. Eberle, U. Mansmann, and C. E. Orfanos, “Elevated plasma levels of transforming growth factor (TGF)-β1 and TGF-β2 in patients with disseminated malignant melanoma,” British Journal of Cancer, vol. 77, no. 9, pp. 1492–1494, 1998. View at Google Scholar · View at Scopus
  13. M. Watanabe, K. Kono, Y. Kawaguchi et al., “NK cell dysfunction with down-regulated CD16 and up-regulated CD56 molecules in patients with esophageal squamous cell carcinoma,” Diseases of the Esophagus, vol. 23, no. 8, pp. 675–681, 2010. View at Publisher · View at Google Scholar
  14. A. Szkaradkiewicz, T. M. Karpiński, M. Drews, M. Borejsza-Wysocki, P. Majewski, and E. Andrzejewska, “Natural killer cell cytotoxicity and immunosuppressive cytokines (IL-10, TGF-β1) in patients with gastric cancer,” Journal of Biomedicine and Biotechnology, vol. 2010, Article ID 901564, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. L. Zhou et al., “Characteristics of peripheral NK cells in hepatocellular carcinomar patients,” Zhonghua Gan Zang Bing Za Zhi, vol. 18, no. 2, pp. 136–139, 1999. View at Google Scholar
  16. J. A. Belisle, J. A. A. Gubbels, C. A. Raphael et al., “Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125),” Immunology, vol. 122, no. 3, pp. 418–429, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. P. Carrega, B. Morandi, R. Costa et al., “Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56brightCD16- cells and display an impaired capability to kill tumor cells,” Cancer, vol. 112, no. 4, pp. 863–875, 2008. View at Publisher · View at Google Scholar
  18. J. C. Lee, K. M. Lee, D. W. Kim, and D. S. Heo, “Elevated TGF-β1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients,” Journal of Immunology, vol. 172, no. 12, pp. 7335–7340, 2004. View at Google Scholar · View at Scopus
  19. D. G. Perez, V. J. Suman, T. R. Fitch et al., “Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A,” Cancer, vol. 115, no. 1, pp. 119–127, 2009. View at Publisher · View at Google Scholar · View at Scopus